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GOODPASTURE SYNDROME: AN INVESTIGATION OF 
DISEASE PROCESS, DIAGNOSIS, TREATMENT, AND 
CONTRIBUTION TO INTRAPULMONARY HEMORRHAGE 
 
JULIA SHIELD, QUEENSLAND UNIVERSITY OF TECHNOLOGY 
MENTOR: MARK B. PLENDERLEITH 
 
Abstract 
Goodpasture syndrome is a rare autoimmune disorder affecting 
approximately one person per million. It is caused by the development of anti-
glomerular basement membrane (GBM) antibodies. Since the description of 
Goodpasture syndrome in 1958, understanding of the syndrome’s pathophysiology 
has significantly increased with advances in molecular biology, delineation of 
immune function, and research into the structure and function of collagen, which 
forms the basement membranes in the alveoli and glomeruli. Although the exact 
trigger for the development of these autoantibodies is unknown, there is a clear 
genetic predisposition in affected individuals with a correlation to human leukocyte 
antigen (HLA) alleles in anti-GBM disease. Environmental factors such as viral 
infection and smoking then damage the alveoli, causing increased permeability and 
increased access to the basement membrane for the autoantibodies. The 
autoimmune response attacks the basement membrane of both alveoli and 
glomeruli, causing pulmonary hemorrhage, hemoptysis, anemia, respiratory failure, 
glomerulonephritis, and renal failure. It is diagnosed by a combination of 
respiratory function tests, chest X-ray, serology for anti-GBM antibodies, and renal 
biopsy. A renal biopsy reveals crescentic glomerulonephritis and linear 
immunofluorescent staining from autoantibody deposition in the capillaries. 
Disease progress is monitored by using these tests serially. Treatment involves 
immunosuppressive medications such as corticosteroids and cyclophosphamide to 
prevent autoantibody production, as well as plasmapheresis to remove 
autoantibodies from circulation. Novel treatment methods currently under 
investigation include immunoadsorption, cryofiltration, and enzymatic 
degradation. Immunoadsorption is a developing therapy with early results showing 
high effectiveness, but further trials are necessary. New developments for using 
enzymatic proteins from the Streptococcus pyogenes bacteria to remove anti-GBM 
autoantibodies that are bound to the actual basement membrane and not just those 
in circulation are currently under investigation. This is facilitated by further recent 
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advances in delineating collagen molecular structure composition in the basement 
membrane. Provided Goodpasture syndrome is diagnosed early, treatment 
regimens are very effective in controlling the disease; however, late-stage disease 
requires dialysis and lung or kidney transplantation. As advances in molecular 
biology and genetics continue, the immune function is mapped in greater detail, 
and genetic susceptibility is better understood, more opportunities to treat 
autoimmune conditions such as Goodpasture syndrome will develop. 
Goodpasture syndrome is a rare autoimmune disorder characterized by the 
destruction of the basement membrane in both the lungs and kidneys (Zhong et al., 
2020). Circulating anti-glomerular basement membrane (GBM) antibodies attach 
to collagen-fiber networks in the membrane, which triggers the membrane’s 
destruction, causing alveolar hemorrhage, resulting in anemia and respiratory 
failure due to impaired gas exchange (Greco et al., 2015). Alveolar hemorrhaging 
from basement-membrane breakdown causes dyspnea, hemoptysis, and chest pain 
(Huart et al., 2016). Given the potential severity of these clinical manifestations, 
pulmonary abnormalities usually become evident before respiratory failure 
develops; however, a rapid diagnosis is essential, as hemorrhage is the leading 
cause of death in individuals with Goodpasture syndrome (Nasser & Cottin, 2018). 
Although the exact trigger of this antibody-induced autoimmune response remains 
unknown, certain environmental factors (e.g., chemical or infectious exposure) 
coupled with genetic susceptibility may lead to its development (Pedchenko et al., 
2018). Diagnosis is achieved by a combined interpretation of respiratory function 
testing, antibody detection through serology, chest X-ray, and lung or kidney 
biopsy. Patients diagnosed with Goodpasture syndrome undergo an array of 
treatment depending on the severity of their condition. Commonly used therapies 
include plasmapheresis, immunosuppression, renal dialysis, and organ 
transplantation. Emerging research has provided numerous opportunities for 
alternative methods of treatment in the near future. The following review will 
utilize current literature and research to investigate the history, epidemiology, 
etiology, and pathophysiology of Goodpasture syndrome. The most common forms 
of diagnostic and treatment procedures will be analyzed. Additional insights for 
emerging research in the field will also be discussed.   
Literature Review 
This review will begin by highlighting the initial investigations of 
Goodpasture syndrome, proceeded by more modernized approaches by relating 
BUTLER JOURNAL OF UNDERGRADUATE RESEARCH, VOLUME 7 
 
 228 
incidence of alveolar hemorrhage to renal failure. Discussion will turn to further 
analysis of contrasting clinical manifestations, diagnostic methods, and treatments.  
Goodpasture syndrome was first described in 1958 by Australian scientists 
Stanton and Tange (Pedchenko et al., 2018), who reported nine cases of rare 
glomerulonephritis with close association to events of idiopathic pulmonary 
hemorrhage. One case study described a man admitted to hospital with anemia, 
hemoptysis, and signs of bronchopneumonia in the right lung and who died after 
three days (Collins, 2010). Urinalysis showed traces of albumin, which is indicative 
of glomerulonephritis. A postmortem examination showed that the terminal 
bronchioles filled with erythrocytes, in addition to necrosis of the alveolar walls 
(Collins, 2010). The authors named the disease in recognition of similar case 
reports described by Dr. Ernest Goodpasture in his 1919 publication on the etiology 
of influenza (Greco et al., 2015). At that time, similar clinical presentations of lung 
hemorrhage linked with glomerulonephritis were attributed to atypical influenza 
infection. Not until the detection of anti-GBM antibodies in the 1960s was a clinical 
description of the pathogenesis for autoimmune-induced Goodpasture syndrome 
possible (Gulati & McAdoo, 2018).  
Since its establishment in 1986, the Vasculitis Foundation has provided 
research funding, educational resources, and networking opportunities for patients 
affected by Goodpasture syndrome and other closely related diseases (National 
Organization for Rare Disorders, 2019). Given the rarity of the disorder, archives 
like these allow continued investigation into the pathophysiological processes and 
controversial etiological implications of the disease. Consequently, the best 
possible diagnosis and treatment options for patients can be provided as research 
progresses.    
Epidemiology and Incidence 
Goodpasture syndrome is a rare disorder, with 0.5 to 1.8 cases per million 
individuals, according to a study published in 2016 that monitored disease numbers 
across 26 countries (Canney et al., 2016). This is similar to previous approximations 
of 1 to 2 cases per million individuals each year across Caucasian populations 
(Gulati & McAdoo, 2018). Some studies report that the disease is more common in 
males than in females, with a 6:1 occurrence ratio (Kaewpu et al., 2020), but an 
investigation from the University of Bari found no significant difference in 
incidence between gender for affected individuals (Dammacco et al., 2013). 
Goodpasture syndrome has a bimodal age distribution, primarily affecting 
individuals between 20 and 30 years and between 60 and 70 years (Betsy et al., 
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2019). Furthermore, it is most common in adults with Caucasian or European 
descent, with African populations less likely affected (Marques et al., 2020).  
Etiology 
Goodpasture syndrome is caused by the production of anti-GBM 
autoantibodies that travel through the bloodstream and mediate the destruction of 
the alveolar and glomerular basement membranes (Nasser & Cottin, 2018). The 
specific trigger for the development of these autoantibodies is not fully understood. 
Certain genetic and environmental influences may contribute to the development 
of this disorder, however (Pedchenko et al., 2018).  
Cases of Goodpasture syndrome are often reported occurring among 
families, which suggests a genetic susceptibility (Gulati & McAdoo, 2018). There 
is a clear correlation with human-leukocyte antigen (HLA) alleles in anti-GBM 
disease, with the antigen HLA-DR15 being found in 88% of affected individuals 
(Nasser & Cottin, 2018). Environmental factors including viruses may contribute 
to the development of the disease by enacting antibodies to fight infection, which 
then cross-react against the basement membrane. Consequently, the body’s 
immune defenses can attack surrounding healthy tissue (Marques et al., 2020). 
Pulmonary hemorrhage is also closely associated with smoking, as cigarette 
contents break down the thin alveolar lining and surrounding capillaries (Nasser & 
Cottin, 2018). 
Pathophysiology 
As discussed, Goodpasture syndrome is caused by the destruction of 
alveolar and glomerular basement membrane by circulating anti-GBM 
autoantibodies. To understand how this process occurs, we must first understand 
the structure and function of antibodies and basement membranes. Investigation 
will turn to the development of secondary outcomes and disruption of the 
physiological processes involved in respiration.  
The autoantibodies reactive with the alveolar and glomerular basement 
membranes are from the IgG class. Pathological antibodies also belong to this class, 
but anti-GBM antibodies belong to subclasses IgG2 and IgG4, which enable 
variation in the fragment antigen-binding domains and therefore specificity in 
binding (Gulati & McAdoo, 2018). Such observations show the significance of 
evaluating the structural and binding features of autoantibodies to understand their 
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ability to trigger an autoimmune response and therefore the pathogenesis of 
Goodpasture syndrome.  
Alveolar basement membranes are extracellular matrices comprising type 
IV collagen, heparan sulphate proteoglycan, laminin, and nidogen (Gulati & 
McAdoo, 2018). Six alpha chains compose the collagen IV family, which bind to 
form unique triple-helical protomer structures (Pedchenko et al., 2018). These 
polymerize to form hexametric structures that provide support to overlying cells. In 
the basement membrane, type IV collagen networks in their native form are 
arranged into triple-helical protomers from α3, α4, and α5 chains (Zhong et al., 
2020). These domains associate to produce the hexameric-NC1 domain. The 
quaternary structure becomes reinforced by hydrophilic, hydrophobic, and 
disulphide bonds across separate domains (Gulati & McAdoo, 2018), and these 
polymerize with other like units to form a lattice network of collagen, as shown in 
Figure 1 (McAdoo & Pusey, 2017). The NC1 domains of collagen protomers arise 
in specific combinations that produce linear arrays found in both the lungs and 
kidneys. 






Figure 1. Collagenous Structure of the Alveolar and Glomerular Basement Membrane  
 
Note. Panels A and B: Structure consists initially of α3, α4, and α5 chains to produce a 
triple helical protomer. Panel C: Association of these protomers produces the 
hexametric NC1 domain. Panel D: Multiple domains bind by hydrophilic and 
hydrophobic interactions to form the lattice structure found in α3(IV)NC1 collagen 
networks. From “Anti-Glomerular Basement Membrane Disease,” by S. McAdoo and C. 




The core target for circulating anti-GBM antibodies is the noncollagenous 
domain (NC1) in the α3 chain of type IV collagen, or α3(IV)NC1 (Gulati & 
McAdoo, 2018). This molecule contains two epitopes, EA and EB, where antibodies 
bind, allowing T-cell recognition to promote a humoral immune response. This is 
also known as the self-antigen, which triggers the autoimmune response in 
Goodpasture syndrome after antibody binding is initiated (Zhong et al., 2020). 
Specific binding of antibodies to the alveolar basement membrane is enabled by the 
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epitopes on self-antigens as well as the arrangement of collagen chains allowing 
easy access to traveling antibodies. In a healthy individual, endothelia in alveoli 
provide a protective barrier so anti-GBM antibodies are unable to bind to these 
epitopes (Hudson et al., 2019), but antibodies can more efficiently bind to the 
epitope units in collagen domains of the basement membrane because of increased 
permeability from either increased capillary hydrostatic pressure or environmental 
factors including smoking and hydrocarbon exposure or pathogenic infection in the 
alveoli (Pedchenko et al., 2018).  
A strong correlation has been shown with Goodpasture syndrome and the 
HLA system. This system aids in human immunity by determining the difference 
between self- and non-self-antigens. HLA-DR15 is one such HLA located in about 
88% of people affected by Goodpasture syndrome (Nasser & Cottin, 2018). The 
high prevalence of these alleles within individuals with the disease highlights a 
potential-genetic predisposition for this rare autoimmune disease; however, certain 
alleles involved with the HLA system are fairly common among unaffected 
populations, suggesting that additional factors are involved in development of the 
disease (Pedchenko et al., 2018). Additionally, a study released in 2016 investigated 
spatial and temporal clustering of cases, which indicates that the presence of 
environmental factors may contribute to provoking disease (Marques et al., 2020). 
Some preexisting damage to the alveolar lining is essential to allow the increased 
permeability that provides access for autoantibodies. Binding can then occur on the 
epitopes on the self-antigens of membranous subunits and activate cascade 
reactions that ultimately result in injury to the lining (Nasser & Cottin, 2018).  
The binding of antibodies to the basement membrane triggers a response via 
two effector mechanisms. In the first, inflammatory processes are activated, which 
enables the mobilization of leukocytes and inflammatory mediators, forming the 
lytic membrane attack complex. The second response involves binding of Fc 
receptors (FcγR) by anti-GBM antibodies (Dammacco et al., 2013). This binding 
action activates phagocytosis and antibody-dependent cellular cytotoxicity to 
produce a strong autoimmune response. There remains a distinguishable correlation 
between the presence of HLA and anti-GBM antibodies in Goodpasture syndrome. 
HLA is a gene complex for major histocompatibility complex (MHC) proteins, 
which help regulate human immunity (Hudson et al., 2019). This shows that T cells 
must be activated before autoantibodies can be generated. After being activated by 
T-helper (Th) lymphocytes, macrophage cells arrive at the site of antibody 
accumulation and produce interferon-(IFN)-γ and interleukin (IL)-12 (Dammacco 
et al., 2013). These cytokines, along with all accumulated cells, induce structural 
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change within the matrix of proteins in the membrane, causing mechanical 
weakness, which leads to eventual irreversible damage. Th1 specific memory cells 
also migrate to the site of inflammation to initiate a delayed hypersensitivity 
response (Zhong et al., 2020). This contributes to most of the damage over time 
once the initial response has been established.  
The complete pathogenic process by which basement membrane destruction 
arises in lungs and kidneys affected with Goodpasture syndrome is illustrated in 
Figure 2.  
 
 
Figure 2. Pathogenic Procedure of Goodpasture Syndrome Leading to Both Pulmonary 
and Renal Damage  
 
Note. Collagenous protomers form with EA and EB epitopes on the α3 collagen chain. 
Disruption of hexamer structure by environmental influences causes exposure of 
epitopes, which allows binding of anti-GBM autoantibodies in genetically susceptible 
individuals. Cellular effectors contribute to damage and inflammation of the basement 
membrane via the autoimmune response. From “Anti–Glomerular Basement 
Membrane Disease,” by K. Gulati and S. McAdoo, 2018, Rheumatic Disease Clinics of 
North America, 44(4), 651-673 https://doi.org/10.1016/j.rdc.2018.06.011).  
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Significant damage to the collagenous microstructure in the alveolar 
basement membrane in turn damages the surrounding alveolar capillaries, causing 
mass hemorrhaging into the alveolar space. The high capacitance but low pressure 
in the-pulmonary-circulation causes chronic low-grade hemorrhage (Greco et al., 
2015). The secondary manifestations of hemoptysis and anemia may consequently 
arise. Gas exchange still occurs with the blood pooled in the alveoli, although 
oxygenation for blood still traveling throughout the pulmonary circulation is no 
longer possible. This can lead to alveolar collapse, ultimately causing hypoxemia 
(Kusunoki et al, 2018). In more-severe cases, this can lead to respiratory failure and 
death.   
Clinical Features and Symptoms 
The most significant feature of Goodpasture syndrome is pulmonary 
hemorrhage leading to hemoptysis (Huart et al., 2016). Severity can range from 
coughing up specks to large volumes of blood. Approximately 80%-90% of patients 
will present with rapidly progressive glomerulonephritis, whereas 40%-60% of 
patients will experience alveolar hemorrhage (McAdoo & Pusey, 2017). Dyspnea 
and chest pain may also precede. Most affected individuals experience hematuria; 
however, glomerulonephritis and acute renal failure can develop weeks to years 
after the onset of pulmonary symptoms (Henderson & Salama, 2017). 
Approximately 60%-80% of patients with Goodpasture syndrome develop clinical 
manifestations of both pulmonary and renal disease, whereas 20%-40% experience 
disease limited to the kidneys. Fewer than 10% have pulmonary disease alone 
(Stojkovikj et al., 2016). The occurrence of clinical and pathological features 
observed in patients is summarized in Figure 3. 
 
 




Figure 3. Summary of Major Clinical and Immunological Features of Patients with 
Goodpasture Syndrome  
 
Note. A range of symptoms from patients was observed, as were the presence of anti-
GBM autoantibodies and proteinuria as a sign of renal failure. From “Anti-Glomerular 
Basement Membrane Disease,” by S. McAdoo and C. Pusey, 2017, Clinical Journal of 




Diagnosis of Goodpasture syndrome involves the accumulation of results 
from serology, renal biopsy, and chest X-ray to create an overall indication of the 
patient’s state. Other tests, such as respiratory function testing, are not routinely 
performed but may be used to indicate signs of hemorrhage in the lungs. The 
disease can become rapidly progressive and fatal if identification and subsequent 
treatment are delayed. Results must therefore be quickly obtained to ensure the best 
possible outcome for the affected individual. 
Serology Test  
Detection of anti-GBM autoantibodies is the most common method of 
diagnosing Goodpasture syndrome. Procedures including indirect 
immunofluorescence testing and direct enzyme-linked immunosorbent assay 
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(ELISA) are used to detect the autoantibodies and confirm diagnosis (Zhong et al., 
2020).  
Assays generally have high specificity and sensitivity, although 5%-10% of 
patients showing anti-GBM antibodies from renal biopsy had false-negative 
serology results when using the assay detection method (Gulati & McAdoo, 2018). 
According to a study by Gulati and McAdoo (2018), this can result from intrinsic 
sensitivity of the assay, antibody disappearance before clinical resolution, or high-
affinity antibodies being rapidly removed from circulation. Similarly, a study by 
Henderson and Salama (2017) found that the ELISA method showed a high 
sensitivity of 95%-100% but a varying specificity of 90%-100%. Serologic testing 
is an urgent laboratory test and can produce tangible results within 24 hours. A 
patient affected by Goodpasture syndrome can deteriorate quickly, so rapid 
diagnosis is essential to early treatment. Approximately 10% of patients with 
Goodpasture syndrome do not always have identifiable antibodies with 
conventional assays, however, so serologic testing should not be the only diagnostic 
procedure performed (McAdoo & Pusey, 2017). If the patient presents with signs 
of glomerulonephritis but no anti-GBM antibodies are detected, a renal biopsy will 
be performed.  
Renal Biopsy 
Because of a higher risk of damage, lung biopsy samples are not regularly 
used to diagnose Goodpasture syndrome. Instead, renal biopsy, in combination with 
a serum assay for anti-GBM antibodies, is preferred and provides a higher yield of 
sample. The procedure involves collecting a sample of kidney tissue that is 
examined using both light and immunofluorescent microscopy to reveal structural 
or necrotic changes in the glomeruli and lines of antibodies attached to the basement 
membrane, as seen in Figure 4 (Gulati & McAdoo, 2018). Immunofluorescent 
staining of tissue reveals a linear deposition of IgG antibodies along the alveolar 
and glomerular capillaries. Such findings are an indication of Goodpasture 
syndrome. Crescent formation in the glomerular tissue is a histopathologic effect 
of anti-GBM disease. Findings from a study by McAdoo and Pusey (2017) suggest 
that 95% of affected individuals have crescent formation of the glomeruli revealed 
by a kidney biopsy. The number of observed crescents in the tissue correlates with 
the level of damage to the kidney.    
 




Figure 4. Kidney Biopsy Sample Using Light Microscopy and Immunofluorescence 
Microscopy for IgG Antibodies  
 
Note. Panel A: Acute crescent formation shows disruption of the basement membrane 
due to fibrinoid necrosis. Panel B: Antibody deposits are revealed along the basement 
membrane, with weaker staining highlighting signs of tissue damage. From “Anti-
Glomerular Basement Membrane Disease,” by K. Gulati and S. McAdoo, 2018, 




Chest X-ray  
A crucial step in the diagnosis of Goodpasture syndrome is detecting the 
presence of hemorrhage within the lung. This is achieved by performing an X-ray 
or CT scan of the thorax. In about 80% of affected individuals, chest X-rays reveal 
bilateral frosted-glass opacities within alveolar regions, as shown in Figure 5 
(Marques et al., 2020). The costophrenic angles and apices of the lungs usually 
remain unaffected. Where diagnosis of lung hemorrhage remains uncertain, a 
bronchoscopy is performed. Diagnosis is based on the absence of bronchial lesions 
which may have led to the alveoli filling with blood from erosion (Marques et al., 
2020). Identification of pulmonary hemorrhage via X-ray is widely accepted, 
although appearance overlaps pulmonary edema (Li et al., 2020), so in the diagnosis 
of Goodpasture syndrome, this method must be included with a respiratory function 
test and antibody detection. 
 




Figure 5. Chest Radiograph of Normal Lungs and Frosted-Glass Opacities  
 
Note. Left panel: Normal lungs. Right panel: Frosted-glass opacities in the lungs caused 
by alveolar hemorrhage. From Comprehensive Clinical Nephrology (5th ed.), by J. 





The main issue regarding diagnosis of this pathology is an extensive 
timeframe, resulting in delayed treatment. As each test cannot provide a definitive 
diagnosis individually, gathering multiple test results before determining the 
patient’s overall state is timely where disease can rapidly progress. Detection of 
anti-GBM antibodies using the serology technique is perhaps the most important 
step in diagnosing Goodpasture syndrome. Despite this technique’s rapid 
completion time, the occurrence of false-negative results reduces its overall 
reliability, and it cannot be used as a sole diagnostic procedure (McAdoo & Pusey, 
2017). As laboratory antigen-detection techniques continue to advance, however, 
the quality of such findings is set to improve for future patients. 
Respiratory Function Testing 
Patients affected with Goodpasture syndrome will produce a quantitative 
change in breathing pattern when assessed by a clinical physiologist using a 
respiratory function test, although this test is not routinely performed. By 
incorporating a standard breathing technique, estimations of diffusing capacity after 
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the inhalation of carbon monoxide can be used to monitor the progression of 
intrapulmonary hemorrhage (Ewan et al., 2019). In the test, the patient inhales a 
gas mixture, which diffuses into the pulmonary capillaries from the alveoli. Carbon 
monoxide uptake depends on the availability of hemoglobin for binding and is 
represented by the rate constant for carbon monoxide transfer (kCO). When 
hemorrhaging has occurred, the alveoli fill with extravascular blood, which allows 
the uptake of additional carbon monoxide (McAdoo & Pusey, 2017). As the 
diffusion of gas from alveolar space to pulmonary capillary is the rate-determining 
step, the removal of this process increases the efficiency by which carbon monoxide 
binds to hemoglobin, overestimating the rate of transfer. The kCO will therefore 
appear abnormally high when corrected for the reduced hemoglobin levels 
(Martínez-Martínez et al., 2017).  
A study published in the British Medical Journal performed the respiratory 
function test on 11 patients with Goodpasture syndrome to determine their kCO 
values in comparison to predicted normal values based on height, gender, and 
ethnicity. As shown in Table 1, kCO values corrected for hemoglobin levels were 
greater than predicted values for most patients (Ewan et al., 2019). This shows that, 
while patients are anemic, high levels of gas diffusion are taking place inside the 
lung due to pooling of blood from alveolar hemorrhage. Measuring carbon 
monoxide intake with the respiratory function test delivers a noninvasive and 
repeatable indication of lung hemorrhage as seen in Goodpasture syndrome 
(McAdoo & Pusey, 2017).  




Table 1. kCO and Hemoglobin Measurements from Respiratory Function Testing for Patients With Goodpasture Syndrome   
 
 Patient 
1 2 3 4 5 6 7 8 9 10 11 
Hemoglobin 
(g/dl) 
6.7 7.5 7.9 5.7 5.3 9.1 7.9 7.2 7.8 7.0 12.1 
Predicted normal 
kCO (%sec-1) 
8.5 7.1 8.8 8.2 7.1 8.5 8.3 7.3 8.2 7.7 6.0 
kCO hemoglobin 
corrected (%sec-1) 
15.0 5.3 13.7 14.8 8.6 10.4 17.4 17.2 12.0 13.0 10.5 
% kCO change 176 -75 156 180 121 122 210 236 146 169 175 
Note. From “Detection of Intrapulmonary Hemorrhage With Carbon Monoxide Uptake—Application in 
Goodpasture’s Syndrome,” by P. Ewan, H. Jones, C. Rhodes, and J. Hughes, 2019, The New England Journal of 
Medicine, 295(25), 1391-1396 (https://doi.org/10.1056/NEJM197612162952502). 




Multiple treatment options for Goodpasture syndrome target the anti-GBM 
antibodies that destroy the alveolar and glomerular basement membrane in an 
autoimmune response. Despite the rarity of this disorder, options to treat both 
aggressive and nonaggressive stages have become available because of recent 
advancements in biomedical technology. Management must immediately follow 
diagnosis, as the disease progresses rapidly and can become fatal. Rapid 
implementation of appropriate treatment initially involved discriminating 
Goodpasture syndrome from other similar pulmonary syndromes. Starting therapy 
despite a negative result for anti-GBM antibodies is still essential, as delay can lead 
to progression of the disease. Therapies currently used include plasmapheresis and 
immunosuppression involving corticosteroid medications. More-severe stages may 
require dialysis and organ transplantation. Treatment for Goodpasture syndrome 
involves three goals: rapid removal of autoantibodies from circulation, prevention 
of further autoantibody production, and removal of potentially harmful agents 
produced from the initial immune response (Nasser & Cottin, 2018).   
Plasmapheresis 
The rapid removal of circulating autoantibodies is achieved by 
plasmapheresis. Even if the patient has not yet been diagnosed with Goodpasture 
syndrome, plasmapheresis can commence following a case of severe pulmonary 
hemorrhage (Greco et al., 2015). The role of plasmapheresis is to remove unwanted 
toxins such as anti-GBM antibodies from the blood, thus eliminating the risk of an 
autoimmune response in the alveoli. In the procedure, blood is removed from the 
patient and the cellular contents and plasma are separated. Donated human-plasma 
replaces the patient’s-original plasma, and then the blood with the donated plasma 
is transfused back into the patient (Saladi et al., 2018). If a bleeding risk occurs 
after pulmonary hemorrhage or renal biopsy in patients, fresh frozen plasma is 
added to maintain normal coagulation. Plasma exchanges of about four liters are 
performed daily for two to three weeks or until anti-GBM antibodies are no longer 
detected (Pedchenko et al., 2018). Despite the usefulness of plasmapheresis in 
ridding the blood of harmful autoantibodies, research regarding side effects and 
overall efficacy is ongoing.  
A study published in 2014 involving 28 patients diagnosed with 
Goodpasture syndrome compared the plasma-exchange methods of plasmapheresis 
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and immunoadsorption. Findings show that both methods produced similar levels 
of effectiveness, with 59.0% and 71.2% efficacy respectively, although only 62.7% 
of patients undergoing plasmapheresis had reduced IgG, compared to 83.5% of 
those undergoing immunoadsorption (Pedchenko et al., 2018). Despite these 
differences, the plasmapheresis group overall experienced fewer plasma-associated 
side effects, making plasmapheresis a safer method of plasma exchange.  
Immunoadsorption is another method of serum-antibody removal that is 
used for multiple autoimmune diseases involving antibody-mediated rejection 
(Saladi et al., 2018). Advocates have proposed immunoadsorption as a therapy in 
anti-GBM disease because of its high-affinity binding of IgG antibody subclasses 
and redundancy of fresh frozen plasma. With this technique, about 87% of IgG 
antibodies can be removed from 2.5 plasma volumes in one session. More than 98% 
of IgG can be cleared after multiple sessions (Henderson & Salama, 2017). 
Plasmapheresis is still the preferred therapy for Goodpasture syndrome, as the 
involvement of immunoadsorption in anti-GBM disease is yet to be properly 
evaluated. Minor case studies of the immunoadsorption method among 10 patients 
showed that antibody levels declined approximately 71%-84% after the initial 
therapy (Henderson & Salama, 2017). This is an improvement on report cases 
involving the plasmapheresis method, but it is not comparable to studies involving 
larger numbers of patients. More investigation into the large-scale effectiveness of 
immunoadsorption is therefore necessary before immunoadsorption can become 
the preferred plasma-exchange treatment for Goodpasture syndrome.  
Immunosuppression  
The prevention of ongoing anti-GBM antibody production is achieved via 
immunosuppression drugs such as corticosteroids and cyclophosphamide. It can 
also prevent rebound hypersynthesis of antibodies after the cessation of 
plasmapheresis (Greco et al., 2015). Reduction of the body’s immune response 
reduces activity of circulating antibodies, including the anti-GBM antibodies, long 
term. This helps lower the occurrence of autoantibody-induced destruction of the 
basement membranous structure in the alveoli and glomeruli. Reduction in the 
body’s ability to produce an immune response consequently leads to a higher risk 
of viral and bacterial infections within patients (Gulati & McAdoo, 2018). 
Corticosteroids and cyclophosphamide are initially administered for 6 and 3 
months, respectively, to reduce immune activity and maintain leucocyte levels in 
the blood (Greco et al., 2015). Therapy durations are not well defined, so the 
presence of anti-GBM antibodies is regularly monitored. Individuals with 
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serologically active disease require an extended period of immunosuppression at 
around 6-9 months. Oral cyclophosphamide is used, as a 2012 study showed that 
intravenously administered cyclophosphamide was linked with increased mortality 
in patients with Goodpasture syndrome (Gulati & McAdoo, 2018). Both rituximab 
and mycophenolate are used as alternative options in treating anti-GBM antibody 
disease if cyclophosphamide use fails or yields severe side effects (Henderson & 
Salama, 2017). The anti-GBM antibodies become undetectable but produce 
variable renal outcomes. 
Following immunosuppressive treatments, adverse side effects, including 
interstitial pneumonitis, erythrocyte aplasia, and thrombocytopenia, are common 
(Diehl et al., 2017). The consumption of such drugs therefore must be carefully 
planned and monitored by a healthcare professional throughout the course of 
treatment. Dosing of 375 milligrams/m2 intravenously once weekly is 
recommended for rituximab, 0.5-3 grams/day for mycophenolate, and 500-1000 
milligrams/m² intravenously monthly for six doses, plus corticosteroids for 
cyclophosphamide (Medscape, 2021a, 2021b, 2021c). Anti-GBM antibody titers 
must be monitored regularly. Once antibody becomes consecutively undetectable, 
plasmapheresis is terminated. Antibody titer procedures are performed monthly as 
a follow-up for at least six months. Corticosteroids are continued for a minimum of 
six months, and cyclophosphamide for three months to help eliminate any 
persisting anti-GBM antibody levels in patients (Segelmark & Hellmark, 2019).  
Substantial evidence supports the effectiveness of plasmapheresis and 
immunosuppression as methods for treating Goodpasture syndrome. One five-year 
study demonstrated that immunosuppressive methods combined with 
plasmapheresis were more effective than was immunosuppression alone (Chung, 
2019). This is because anti-GBM antibodies are more efficiently removed, allowing 
for faster patient recovery and less tissue damage. A research study conducted on 
the molecular basis of Goodpasture syndrome compared the effects of 
immunosuppression therapy with and without the use of plasmapheresis and found 
the mortality rate decreased 11% with the combined treatment (Betsy et al., 2019). 
This shows that although each treatment method is effective in alleviating the 
consequences of the autoimmune response, the best possible outcome for the 
patient is achieved when both therapies are employed simultaneously.  
Dialysis  
The final goal in treatment for Goodpasture syndrome is the removal of 
potentially harmful agents generated from the initial immune response. This 
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involves dialysis or the removal of excess toxins and solutes from the blood. 
Because of glomerular membrane damage, patients need regular checks to monitor 
renal function (Saladi et al., 2018). If the kidney can no longer function to an 
adequate level, dialysis will be performed indefinitely as a replacement therapy. 
Referral for organ transplantation may additionally be recommended, depending on 
suitability and availability. End-stage renal disease is still possible after renal 
dialysis, though only about 30% of surviving patients require this treatment method 
(Pedchenko et al., 2018).  
Organ Transplantation 
In the most severe cases of Goodpasture syndrome, affected individuals 
may receive lung or kidney transplants, depending on the level of original function 
lost. Patients who receive transplants can have a recurrence of anti-GBM antibody 
levels, causing relapse (Gulati & McAdoo, 2018). A patient should therefore wait 
about six months after plasmapheresis and immunosuppression before receiving a 
transplant, to ensure seronegativity with anti-GBM antibodies. This will reduce the 
risk of damage to the transplanted organ. Relapses are uncommon, however, and 
are associated with prolonged exposure to environmental factors such as irritants 
and smoking (Rohm et al., 2019).  
Future Directions 
There are several emerging directions for the management and treatment of 
Goodpasture syndrome. As research on this rare disease progresses, new 
mechanisms for understanding pathogenesis and treatment are under development. 
Collagen research and novel methods of plasma exchange are some of the areas 
currently under investigation. 
Research regarding the type IV collagen family provides new information 
about the structural development of basement membranes in the alveoli and 
glomeruli. By understanding the biochemical nature of these collagen molecules 
acting as antigens in the autoimmune response, the molecular understanding of 
protomer assembly in the pathogenesis of Goodpasture syndrome can be better 
understood (Hudson et al., 2019). Certain developing insights suggesting 
membranous susceptibility to proteolysis can lead to the development of certain 
protease inhibitors and genetic therapy. Experimental models of this disease predict 
the potential use for costimulatory blockade of T-cell activation or prevention of 
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macrophage migration (Hudson et al., 2019). This work will provide a new 
understanding of collagen-related diseases such as Goodpasture syndrome. 
More specific methods of plasmapheresis are being investigated for the 
treatment of Goodpasture syndrome. Some of these include immunoadsorption, 
cryofiltration, and enzymatic degradation. Current methods of plasma exchange are 
useful for removing anti-GBM antibodies that are in circulation but not those bound 
to tissue (Henderson & Salama, 2017). New approaches to this problem are under 
investigation, including exploration of the properties of proteins S. pyogenes (IdeS) 
and endoglycosidase (EndoS), which are secreted by the bacteria Streptococcus 
pyogenes. Human IgG antibodies are cleaved by IdeS, which produces monomeric 
Fc fragments (Henderson & Salama, 2017). This hinders the antibody’s ability to 
function. An experimental model of glomerulonephritis demonstrated the 
successful removal of glomerular Fc fragments of anti-GBM by IdeS, showing its 
effectiveness as an immunosuppressant. IdeS trials have progressed mainly in 
kidney transplantation but currently have directed clinical trials toward anti-GBM 
disease (Li et al., 2020). As previously mentioned, immunoadsorption removes 
circulating anti-GBM antibodies with the use of sepharose-coupled antihuman IgG 
but needs comprehensive validation before becoming an accepted technique.  
Conclusion 
Despite its rarity, Goodpasture syndrome has become increasingly better 
understood since its initial description in 1958. Given the discovery of antibodies 
and advancements in the field of molecular biology, affected individuals are able 
to be diagnosed and treated through various methods. Effective patient 
management is frequently achieved. The production of false-negative serology 
results reduces the overall reliability of the diagnostic procedure, however. As the 
disease can progress rapidly, an accurate diagnosis allowing for immediate 
treatment is essential to prevent any detrimental consequences in the patient’s 
health. Immunoadsorption and other alternate methods of treatment are being 
researched and undergoing trials, with the potential of improving therapy efficacy. 
Research into the type IV collagen family is also being conducted to improve 
overall molecular understanding of the pathogenesis and progression of the disease 
process. This may result in significant changes to the approach of disease 
management and may improve patient recovery for future practice.  
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